Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Salarius Pharmaceuticals Announces Agreement With DeuteRx To Acquire An Oral, Small Molecule Targeted Protein Degradation Portfolio; DeuteRx Will Receive From Salarius An Upfront Payment Consisting Of $1.5M In Cash And 1M Shares Of Restricted Stock

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced a definitive

SLRX